Molecular Imaging

Employing AI-powered automation, the MIM LesionID™ Pro reportedly bolsters the efficiency of whole-body tumor burden analysis with PSMA PET/CT and SPECT/CT.

In recent interviews, Rajesh Bhayana, M.D., Manisha Bahl, M.D., and Jeremie Calais, M.D., Ph.D., shared their thoughts on agentic AI, key directions in breast imaging research and emerging trends with prostate cancer theranostics in 2026.

Catch up on the top radiology content of the past week.

The upgraded RefleXion X2 platform offers a 20 cm field of view that may bolster visualization of moving tumors.

In a recent interview, Onofrio Catalano, M.D., Ph.D., discussed new research findings demonstrating robust sensitivity and specificity in detecting hepatocellular carcinoma in patients with LI-RADS 3 presentations.

In a recent interview, Jeremie Calais, M.D., Ph.D., discussed new research examining the prognostic capacity of PSMA PET parameters in predicting hematologic toxicity and outcomes for patients treated with (177Lu)Lu-PSMA-617 for mCRPC.

Catch up on the most popular radiology podcasts from 2025.

In a recent interview, Michael Hofman, MBBS, FRACP, discussed preliminary research findings and the potential utility of the positron emission tomography (PET) agent ITM-94, which recently garnered a fast track designation from the FDA for clear cell renal cell carcinoma (ccRCC).

Catch up on the most well-viewed prostate cancer imaging content from 2025.

Catch up on the top radiology content of the past week.

For patients with primary lung cancer, a nomogram incorporating PET, CT and clinical findings offered an 87.7 percent AUC for predicting lymph node metastasis and over a 19 percent higher sensitivity than a PET-based model for predicting small lymph node ( > 1 cm) metastasis.

Irregular CT margin and an SUVmax > 6.25 were associated with greater than threefold and sixfold higher risks, respectively, for malignancy among patients with thyroid incidentalomas detected on PET/CT, according to new research.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

Catch up on the most well-viewed video interviews from Diagnostic Imaging in November 2025.

Catch up on the most-well viewed radiology content in November 2025.

Utilizing the AI-enabled TrackPSMA to monitor the effectiveness of radioligand therapy for prostate cancer may allow more timely decisions to adjust treatment dosage or switch to a more effective modality.

Catch up on the top radiology content of the past week.

The gallium-68 radiolabeled PET imaging agent ITM-94 is currently being evaluated in a phase 1/2 trial for its utility in detecting ccRCC and differentiating indeterminate renal masses.

Catch up on the top radiology content of the past week.

In a prospective study comparing PSMA PET/CT and mpMRI for biopsy- and imaging-naïve men with suspected prostate cancer (PCa), PSMA PET/CT led to altered management in 34 percent of confirmed cases of PCa.

Catch up on the top radiology content of the past week.

In the second part of a recent interview on new molecular imaging guidelines for renal masses, Steven Rowe, M.D., discussed the off-label utility of the mitochondrial imaging agent 99mTc-sestamibi and the potential role of AI in advanced imaging for indeterminate renal masses.

In a new review from the European Society of Urogenital Radiology (ESUR), researchers discuss the merits and limitations of PSMA PET/CT and whole-body MRI (WB-MRI) for patients with advanced prostate cancer.

In a recent interview, Steven Rowe, M.D., discussed pertinent insights from recently published molecular imaging guidelines for renal masses and the potential of 89Zr-girentuximab for clear cell renal cell carcinoma (ccRCC).